

Senate File 470 - Introduced

SENATE FILE 470
BY COMMITTEE ON HUMAN
RESOURCES

(SUCCESSOR TO SF 282)

(COMPANION TO HF 520 BY
COMMITTEE ON PUBLIC SAFETY)

A BILL FOR

1 An Act relating to the medical use of cannabidiol including the
2 scheduling of a cannabidiol investigational product approved
3 as a prescription drug medication under federal law and
4 including effective date provisions.
5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

1 Section 1. NEW SECTION. 124.201A Cannabidiol
2 investigational product — rules.

3 1. If a cannabidiol investigational product approved as
4 a prescription drug medication by the United States food and
5 drug administration is eliminated from or revised in the
6 federal schedule of controlled substances by the federal drug
7 enforcement agency and notice of the elimination or revision
8 is given to the board, the board shall similarly eliminate
9 or revise the prescription drug medication in the schedule
10 of controlled substances under this chapter. Such action by
11 the board shall be immediately effective upon the date of
12 publication of the final regulation containing the elimination
13 or revision in the federal register.

14 2. The board shall adopt rules pursuant to chapter 17A
15 to administer this section. The board may adopt rules on an
16 emergency basis as provided in section 17A.4, subsection 3, and
17 section 17A.5, subsection 2, to administer this section, and
18 the rules shall be effective immediately upon filing unless
19 a later date is specified in the rules. Any emergency rules
20 adopted in accordance with this section shall also be published
21 as a notice of intended action as provided in section 17A.4,
22 subsection 1.

23 Sec. 2. REPEAL. Section 124D.8, Code 2017, is repealed.

24 Sec. 3. EFFECTIVE DATE. The section of this Act repealing
25 section 124D.8, Code 2017, takes effect June 30, 2017.

26 EXPLANATION

27 The inclusion of this explanation does not constitute agreement with
28 the explanation's substance by the members of the general assembly.

29 This bill relates to the medical use of cannabidiol,
30 including the scheduling of a cannabidiol investigational
31 product approved as a prescription drug medication under
32 federal law.

33 The bill provides if a cannabidiol investigational product
34 approved as a prescription drug medication by the United States
35 food and drug administration is eliminated from or revised in

1 the federal schedule of controlled substances by the federal
2 drug enforcement agency and notice of the elimination or
3 revision is given to the board, the board of pharmacy shall
4 similarly eliminate or revise the prescription drug medication
5 in the schedule of controlled substances under Code chapter
6 124. Such action by the board shall be immediately effective
7 upon the date of publication of the final regulation containing
8 the elimination or revision in the federal register.

9 The bill provides that the board shall adopt rules pursuant
10 to Code chapter 17A to administer the bill and may adopt
11 emergency rules which shall be effective immediately upon
12 filing unless a later date is specified in the rules. Any
13 emergency rules adopted shall also be published as a notice of
14 intended action as provided in Code section 17A.4, subsection
15 1.

16 The bill strikes the repeal of Code chapter 124D (medical
17 cannabidiol Act) before the repeal becomes effective July 1,
18 2017.